As shown in Figure S2, regardless of IDH status or TMB, all glioma groups showed similarly high percentage of immune cells classified as M2 macrophages, but no significant difference between groups (one-way ANOVA test, p = 0.78) (Figure S3A). This evidence concerns the gene IDH1 and central nervous system cancer.